Cargando…
Gene expression profiling as a prognostic tool in multiple myeloma
Multiple myeloma (MM) is an aggressive plasma cell malignancy with high degrees of variability in outcome, some patients experience long remissions, whilst others survive less than two years from diagnosis. Therapy refractoriness and relapse remain challenges in MM management, and there is a need fo...
Autores principales: | Black, Harmony, Glavey, Siobhan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992436/ https://www.ncbi.nlm.nih.gov/pubmed/35582380 http://dx.doi.org/10.20517/cdr.2021.83 |
Ejemplares similares
-
Genetic Abnormalities in Extramedullary Multiple Myeloma
por: McAvera, Roisin, et al.
Publicado: (2023) -
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
por: Swan, Dawn, et al.
Publicado: (2023) -
Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma
por: Comerford, Claire, et al.
Publicado: (2022) -
Adoptive Immunotherapy and High-Risk Myeloma
por: Duane, Catherine, et al.
Publicado: (2023) -
The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies
por: Comerford, Claire, et al.
Publicado: (2022)